Actively Recruiting
Evaluation of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Adults with Advanced Solid Tumors
Led by Virogin Biotech Ltd. · Updated on 2026-09-22
42
Participants Needed
1
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating VG2025, a Recombinant Human IL1215 Dual-Regulated Oncolytic HSV-1 Injection, in adults with advanced malignant solid tumors that have not responded to standard therapies. This open-label Phase IIIa study focuses on patients who test positive for herpes simplex virus HSV-1 antibodies. The main goal is to determine the safety, tolerability, and appropriate dosing of VG2025 for future trials. Participants will receive VG2025 intravenously following a standard 33 dose-escalation design across up to seven dose levels. The study includes up to 42 HSV-seropositive subjects and proceeds with cohorts of three patients each. This design helps identify the maximum tolerated dose and recommended Phase II dose. The treatment period is monitored closely for adverse effects and dose-limiting toxicities. During the study, participants will be regularly evaluated for safety through adverse event tracking and laboratory tests over 12 months. Researchers will also monitor pharmacokinetics, immune response markers such as interleukin levels, tumor DNA levels, and clinical outcomes like response rates and disease control. Safety and efficacy correlations with cancer biomarkers will be assessed. The total participation duration extends up to three years, including follow-up and monitoring periods.
CONDITIONS
Brief Title
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors
Research Team
J
Jia bin Jin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here